Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy Academic Article uri icon

Overview

MeSH Major

  • 3-Iodobenzylguanidine
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Marrow
  • Neuroblastoma
  • Radiopharmaceuticals

abstract

  • With the less effective therapy consequent to the intensification of induction only after initial exposure to standard-dose chemotherapy, MIBG scintigraphy merely confirms the findings of other staging modalities for detection of relatively widespread residual NB. However, when dose-intensive therapy is initiated at diagnosis, the reliable achievement of major disease responses makes extensive BM testing and MIBG scintigraphy prerequisites for accurate determination of disease status.

publication date

  • March 15, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2003.07.142

PubMed ID

  • 12637474

Additional Document Info

start page

  • 1082

end page

  • 6

volume

  • 21

number

  • 6